|
gptkbp:instanceOf
|
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:amendedBy
|
gptkb:T_cells
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:clinicalTrialPhase
|
II
III
I
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Carl_June
gptkb:Michel_Sadelain
|
|
gptkbp:futureDirection
|
improved safety
expanded indications
off-the-shelf therapies
|
|
gptkbp:hasApprovedDrug
|
gptkb:Kymriah
gptkb:Yescarta
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
T Cell Therapy
|
|
gptkbp:includes
|
gene therapy
TCR-T cell therapy
|
|
gptkbp:involves
|
genetic engineering
|
|
gptkbp:monitors
|
biomarkers
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:requires
|
cell expansion
leukapheresis
cell modification
conditioning chemotherapy
|
|
gptkbp:sideEffect
|
neurotoxicity
cytokine release syndrome
|
|
gptkbp:studiedBy
|
gptkb:University_of_Pennsylvania
gptkb:MD_Anderson_Cancer_Center
gptkb:National_Cancer_Institute
gptkb:Memorial_Sloan_Kettering_Cancer_Center
oncologists
immunologists
|
|
gptkbp:target
|
cancer cells
|
|
gptkbp:usedFor
|
gptkb:cancer
solid tumors
hematologic malignancies
autoimmune disease treatment
|
|
gptkbp:bfsParent
|
gptkb:Cell_Therapy
|
|
gptkbp:bfsLayer
|
6
|